Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Albuterol sulfate and budesonide

Drug class: Corticosteroid

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Albuterol sulfate and budesonide key facts

Drug class
Corticosteroid
Used for
AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Typical pharmacy cost
$45.03 per gram (albuterol sulfate 90 ug · budesonide 80 ug; NADAC)
Latest FDA recall
May 14, 2025 (Class II)

Sources: FDA label (September 18, 2025); FDA NDC Directory (November 13, 2026); CMS NADAC (November 11, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Albuterol sulfate and budesonide used for?
The FDA-approved label (Airsupra, AstraZeneca Pharmaceuticals LP, September 18, 2025) says: “AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. AIRSUPRA is a combination of albuterol, a beta 2 -adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Albuterol sulfate and budesonide?
The “Adverse Reactions” section of the FDA label (Airsupra, AstraZeneca Pharmaceuticals LP, September 18, 2025) begins: “The following clinically significant adverse reactions are described elsewhere in labeling: • Deterioration of Asthma [see Warnings and Precautions (5.1)] • Paradoxical Bronchospasm [see Warnings and Precautions (5.2)] • Cardiovascular Effects [see Warnings and Precautions (5.3)] • Hypersensitivity Reactions, including Anaphylaxis [see Warnings and Precautions (5.5)] • Hypokalemia [see Warnings and Precautions (5.7)] • Immunosuppression and Risk of Infections [see Warnings …” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Albuterol sulfate and budesonide?
The “Drug Interactions” section of the FDA label (Airsupra, AstraZeneca Pharmaceuticals LP, September 18, 2025) begins: “No formal drug interaction studies have been performed with AIRSUPRA. • Strong cytochrome P450 3A4 inhibitors (e.g. ritonavir): Use with caution. May cause systemic corticosteroid effects. (7.1) • Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7.2) • Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Albuterol sulfate and budesonide have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Albuterol sulfate and budesonide?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Albuterol sulfate and budesonide been recalled?
FDA enforcement reports list 1 recall of products of this medicine; the newest started May 14, 2025 (Class II). A recall usually concerns specific lots, not every product.
Who makes Albuterol sulfate and budesonide?
1 company lists prescription products of Albuterol sulfate and budesonide in the FDA NDC Directory, including AstraZeneca Pharmaceuticals LP.

What Albuterol sulfate and budesonide is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. AIRSUPRA is a combination of albuterol, a beta 2 -adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma …

— FDA label: Airsupra, AstraZeneca Pharmaceuticals LP, effective September 18, 2025. Read the full label on DailyMed →

Label quoted: the one for the most common form (aerosol, metered, respiratory (inhalation)), Airsupra, AstraZeneca Pharmaceuticals LP; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Albuterol sulfate and budesonide side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following clinically significant adverse reactions are described elsewhere in labeling:

  • Deterioration of Asthma [see Warnings and Precautions (5.1)]
  • Paradoxical Bronchospasm [see Warnings and Precautions (5.2)]
  • Cardiovascular Effects [see Warnings and Precautions (5.3)]
  • Hypersensitivity Reactions, including Anaphylaxis [see Warnings and Precautions (5.5)]
  • Hypokalemia [see Warnings and Precautions (5.7)]
  • Immunosuppression and Risk of Infections [see Warnings …

— FDA label: Airsupra, AstraZeneca Pharmaceuticals LP, effective September 18, 2025. This is part of the section. Read the full label on DailyMed →

Albuterol sulfate and budesonide drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

No formal drug interaction studies have been performed with AIRSUPRA.

  • Strong cytochrome P450 3A4 inhibitors (e.g. ritonavir): Use with caution. May cause systemic corticosteroid effects. (7.1)
  • Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7.2)
  • Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm.
Read more of this section

When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7.3)

  • Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7.4)
  • Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7.5)
  • Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7.6) 7.1 Inhibitors of Cytochrome P450 3A4 The main route of metabolism of corticosteroids, including budesonide, a component of AIRSUPRA, is via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4). After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased. Concomitant administration of a CYP3A4 inhibitor may inhibit the metabolism of, and increase the systemic exposure to, budesonide. Caution should be exercised when considering the co-administration of AIRSUPRA with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Warnings and Precautions (5.11)]. 7.2 Use with Other Short-Acting Bronchodilators AIRSUPRA contains the short-acting beta-agonist, albuterol. Therefore, concomitant use of additional beta-agonists with AIRSUPRA should be used judiciously to prevent beta-agonist overdose. 7.3 Beta-Blockers Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as albuterol, a component of AIRSUPRA, but may also produce severe bronchospasm in patients with asthma. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic-blocking agents in these patients. In this setting, consider cardioselective beta-blockers, although they should be administered with caution. 7.4 Diuretics The ECG changes and/or hypokalemia which may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of AIRSUPRA with non-potassium-sparing diuretics.

— FDA label: Airsupra, AstraZeneca Pharmaceuticals LP, effective September 18, 2025. This is part of the section. Read the full label on DailyMed →

Albuterol sulfate and budesonide dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

  • Recommended Dosage: AIRSUPRA 180 mcg/160 mcg (administered as 2 actuations of albuterol/budesonide 90 mcg/80 mcg) by oral inhalation as needed for asthma symptoms. (2.1)
  • Do not take more than 6 doses (12 inhalations) in a 24-hour period. (2.1)
  • Prime inhaler prior to first use. Re-prime when inhaler has not been used for more than 7 days, is dropped, or after cleaning. (2.2)
  • Discard when the dose counter displays 0.
Read more of this section

(2.3) 2.1 Recommended Dosage and Administration The recommended dosage of AIRSUPRA is albuterol 180 mcg and budesonide 160 mcg (administered as 2 actuations of AIRSUPRA [albuterol/budesonide 90 mcg/80 mcg]) as needed for asthma symptoms by oral inhalation. Do not take more than 6 doses (12 inhalations) in a 24-hour period [see Warnings and Precautions (5.4)]. 2.2 Priming Before Use

  • Priming AIRSUPRA is essential to ensure appropriate drug content in each actuation. Prime AIRSUPRA before using for the first time. To prime AIRSUPRA, release 4 sprays into the air away from the face, shaking well before each spray.
  • AIRSUPRA must be re-primed when the inhaler has not been used for more than 7 days, is dropped, or after cleaning. To re-prime AIRSUPRA, release 2 sprays into the air away from the face, shaking well before each spray. 2.3 Dose Counter The canister has an attached dose indicator (also known as puff indicator) which indicates how many inhalations (puffs) remain. The dose indicator pointer will move after every actuation. The pointer will show the number of inhalations remaining in the canister. When nearing the end of the usable inhalations, the color behind the number in the dose indicator display window changes to yellow. AIRSUPRA should be discarded when the pointer reaches zero.

— FDA label: Airsupra, AstraZeneca Pharmaceuticals LP, effective September 18, 2025. Read the full label on DailyMed →

Albuterol sulfate and budesonide in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asthma medications during pregnancy. For more information, contact the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists at 1-877-311-8972 or visit http://mothertobaby.org/pregnancy-studies/.

Read more of this section

Risk Summary Available data from published case series, epidemiological studies and reviews with budesonide use in pregnant women have not identified a drug-related risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Available data from epidemiological studies and postmarketing case reports of pregnancy outcomes following inhaled albuterol use do not consistently demonstrate a risk of major birth defects or miscarriage. The available epidemiological studies have methodologic limitations, including inconsistent comparator groups, definitions of outcomes, and assessment of disease impact. There are risks to the mother and fetus associated with asthma in pregnancy (see Clinical Considerations). Animal reproduction studies have not been conducted with AIRSUPRA, however, animal studies are available with its individual components, albuterol and budesonide. Administration of albuterol to mice and rabbits during the period of organogenesis revealed evidence of adverse developmental outcomes (cleft palate in mice, delayed ossification in rabbits) at less than maximum recommended human daily inhalation dose (MRHDID) (see Data). In animal reproduction studies, budesonide, administered by the subcutaneous route, caused structural abnormalities, was embryocidal, and reduced fetal weights in rats and rabbits at less than the MRHDID in adults, but these effects were not seen in rats that received inhaled doses approximately 2.5 times the MRHDID in adults (see Data). Experience with oral corticosteroids suggests that rodents are more prone to structural abnormalities from corticosteroid exposure than humans. The background risk of major birth defects and miscarriage of the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal risk In women with poorly or moderately controlled asthma, there is an increased risk of several perinatal adverse outcomes such as preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate. Pregnant women with asthma should be closely monitored and medication adjusted as necessary to maintain optimal asthma control. Labor or Delivery Because of the potential for beta-agonist interference with uterine contractility, use of AIRSUPRA during labor should be restricted to those patients in whom the benefits clearly outweigh the risk. AIRSUPRA has not been approved for the management of pre-term labor.

— FDA label: Airsupra, AstraZeneca Pharmaceuticals LP, effective September 18, 2025. This is part of the section. Read the full label on DailyMed →

When Albuterol sulfate and budesonide should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

AIRSUPRA is contraindicated in patients with a history of hypersensitivity to albuterol, budesonide, or any of the excipients [see Warnings and Precautions (5.5), Description (11)]. Hypersensitivity to albuterol, budesonide, or to any of the excipients. (4)

— FDA label: Airsupra, AstraZeneca Pharmaceuticals LP, effective September 18, 2025. Read the full label on DailyMed →

Albuterol sulfate and budesonide overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

AIRSUPRA contains both albuterol and budesonide; therefore, the risks associated with overdosage for the individual components described below apply to AIRSUPRA.

Read more of this section

Albuterol The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms of beta-adrenergic stimulation (e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/minute, arrhythmias, nervousness, headache, tremor, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, and metabolic acidosis). Hypokalemia may also occur. As with all sympathomimetic medications, cardiac arrest and even death may be associated with abuse of AIRSUPRA. Treatment consists of discontinuation of AIRSUPRA together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of AIRSUPRA. Budesonide If used at excessive doses for prolonged periods, systemic corticosteroid effects such as hypercorticism may occur [see Warnings and Precautions (5.10)].

— FDA label: Airsupra, AstraZeneca Pharmaceuticals LP, effective September 18, 2025. Read the full label on DailyMed →

Forms and how it is given

Dosage formsAerosol, metered
RouteRespiratory (inhalation)
Prescription products1 in the FDA NDC Directory
Brand namesAirsupra

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Albuterol sulfate and budesonide, by strength and form
Strength and formGeneric or brandPharmacies pay
albuterol sulfate 90 ug · budesonide 80 ug
aerosol, metered
Brand: Airsupra $45.03 per gram

NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA214070
AIRSUPRA
AstrazenecaJanuary 10, 2023 1, latest September 15, 2025
2025: Efficacy

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.

  1. May 14, 2025 · Class II · Ongoing · D-0444-2025

    Defective delivery system

    Airsupra (albuterol and budesonide) inhalation aerosol, 90 mcg/80 mcg per inhalation, packaged in a) 120-inhalation canister (NDC 0310-9080-12) b) 28-inhalation canister (NDC 0310-9080-28), Rx only, Manufactured for: Ast — AsttraZeneca Pharmaceuticals LP

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Official identifiers

RxCUI (RxNorm)2665906, 2665912, 2678391, 2678392
SPL set ID of the quoted labele60aa9f9-5139-44df-b886-ebddc3c7eb13
FDA labels (SPL)1
FDA applicationsNDA214070
Active ingredients (FDA)ALBUTEROL / BUDESONIDE

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Airsupra, AstraZeneca Pharmaceuticals LP, effective September 18, 2025; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers